Theragenics
Private Company
Funding information not available
Overview
Theragenics is a well-established, commercial-stage medical device company specializing in brachytherapy and radioisotope production. Its core business involves manufacturing low-dose-rate (LDR) brachytherapy seeds (e.g., TheraSeed Pd-103, AgX100 I-125, Cs-131) and operating a significant radioisotope contract manufacturing organization (CMO) facility. With a 40+ year history, the company serves the global oncology market by providing critical components for localized cancer treatment and enabling the development of novel radiopharmaceuticals for partners. Its integrated model from isotope production to finished device positions it as a key infrastructure player in the targeted radiotherapy space.
Technology Platform
Integrated platform combining commercial-scale medical radioisotope production (using cyclotrons) with the design and manufacturing of Low-Dose-Rate (LDR) brachytherapy seeds and delivery systems. Provides end-to-end capabilities from raw isotope to finished medical device.
Opportunities
Risk Factors
Competitive Landscape
In brachytherapy, Theragenics competes with other seed manufacturers like Bard (BD) and Isoray. In radioisotope production, it faces competition from large pharma (e.g., Novartis, Bayer), government labs (e.g., DOE), and other CMOs. Its integrated model and US-based scale provide a competitive differentiator in a supply-constrained market.